Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report released on Sunday. The firm issued a sell rating on the biotechnology company’s stock.

Cellectis Stock Performance

CLLS opened at $1.90 on Friday. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average price is $2.17 and its two-hundred day moving average price is $2.35. The firm has a market capitalization of $105.61 million, a P/E ratio of -1.47 and a beta of 3.09. Cellectis has a 12-month low of $0.96 and a 12-month high of $3.77.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.05. The business had revenue of $9.50 million for the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. On average, equities analysts forecast that Cellectis will post -0.54 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

Several hedge funds have recently made changes to their positions in CLLS. First Affirmative Financial Network acquired a new position in Cellectis in the 3rd quarter valued at approximately $45,000. Long Focus Capital Management LLC grew its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Cellectis during the second quarter valued at approximately $29,000. Principal Financial Group Inc. raised its stake in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its position in Cellectis by 1.3% in the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after purchasing an additional 10,605 shares during the period. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.